People · Operator
Named in public records as an officer, director or promoter · active 2009–2021 · Biotechnology, Pharmaceuticals, Environmental Services, Other, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Sagimet Biosciences Inc. | — | Biotechnology | Series C | $166.6M | $2.4B | 2009 |
| Trevena Inc | — | Pharmaceuticals | Series C | $77.5M | $2.1B | 2010 |
| Cardioxyl Pharmaceuticals Inc | — | Pharmaceuticals | Series B | $52.0M | $953.8M | 2009 |
| Disa Technologies, Inc. | — | Environmental Services | Series B | $50.8M | $82.8M | 2019 |
| Zyngenia, Inc. | — | Other | Series A | $18.0M | $151.3M | 2009 |
| Boss Controls, LLC | — | Other Technology | Seed | $5.4M | $28.1M | 2014 |
| IntelliSpeX, Inc. | — | Other Technology | Seed | $2.2M | $75.5M | 2019 |
Robert Garland at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Garland on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Lee | 1 | 20 |
| Beth Seidenberg | 1 | 15 |
| David Mott | 1 | 9 |
| David Solomon | 1 | 8 |
| Gordon Ringold | 1 | 7 |
| Christopher Mirabelli | 1 | 6 |
| Farah Champsi | 1 | 5 |
| Peter A. Thompson | 1 | 5 |
| Jeff Clark | 1 | 5 |
| Ralph Snyderman | 1 | 4 |
| Peter Kiener | 1 | 4 |
| Maxine Gowen | 1 | 4 |
| James Young | 1 | 4 |
| Richard Rodgers | 1 | 4 |
| Christopher A. Kroeger | 1 | 4 |
| John Barrett | 1 | 4 |
| Charles A. Sanders | 1 | 3 |
| Peter A. Kiener | 1 | 3 |
| Marty Reed | 1 | 3 |
| Michael Torosian | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.